Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates
Waning protective efficacy of mRNA-based booster vaccinations has been observed against newly emerging SARS-CoV-2 variants of concern. In this work, Pavot et al. formulate a monovalent Beta vaccine and demonstrate durable cross-neutralising antibody responses in non-human primates, against a spectru...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-36908-z |
| _version_ | 1797864092366536704 |
|---|---|
| author | Vincent Pavot Catherine Berry Michael Kishko Natalie G. Anosova Lu Li Tim Tibbitts Dean Huang Alice Raillard Sylviane Gautheron Cindy Gutzeit Marguerite Koutsoukos Roman M. Chicz Valerie Lecouturier |
| author_facet | Vincent Pavot Catherine Berry Michael Kishko Natalie G. Anosova Lu Li Tim Tibbitts Dean Huang Alice Raillard Sylviane Gautheron Cindy Gutzeit Marguerite Koutsoukos Roman M. Chicz Valerie Lecouturier |
| author_sort | Vincent Pavot |
| collection | DOAJ |
| description | Waning protective efficacy of mRNA-based booster vaccinations has been observed against newly emerging SARS-CoV-2 variants of concern. In this work, Pavot et al. formulate a monovalent Beta vaccine and demonstrate durable cross-neutralising antibody responses in non-human primates, against a spectrum of variants. |
| first_indexed | 2024-04-09T22:47:04Z |
| format | Article |
| id | doaj.art-82bb567df3234c4eb6b85d8731df0e1a |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-09T22:47:04Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-82bb567df3234c4eb6b85d8731df0e1a2023-03-22T11:48:41ZengNature PortfolioNature Communications2041-17232023-03-011411810.1038/s41467-023-36908-zBeta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primatesVincent Pavot0Catherine Berry1Michael Kishko2Natalie G. Anosova3Lu Li4Tim Tibbitts5Dean Huang6Alice Raillard7Sylviane Gautheron8Cindy Gutzeit9Marguerite Koutsoukos10Roman M. Chicz11Valerie Lecouturier12SanofiSanofiSanofiSanofiSanofiSanofiSanofiSanofiSanofiGSKGSKSanofiSanofiWaning protective efficacy of mRNA-based booster vaccinations has been observed against newly emerging SARS-CoV-2 variants of concern. In this work, Pavot et al. formulate a monovalent Beta vaccine and demonstrate durable cross-neutralising antibody responses in non-human primates, against a spectrum of variants.https://doi.org/10.1038/s41467-023-36908-z |
| spellingShingle | Vincent Pavot Catherine Berry Michael Kishko Natalie G. Anosova Lu Li Tim Tibbitts Dean Huang Alice Raillard Sylviane Gautheron Cindy Gutzeit Marguerite Koutsoukos Roman M. Chicz Valerie Lecouturier Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates Nature Communications |
| title | Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates |
| title_full | Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates |
| title_fullStr | Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates |
| title_full_unstemmed | Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates |
| title_short | Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates |
| title_sort | beta variant covid 19 protein booster vaccine elicits durable cross neutralization against sars cov 2 variants in non human primates |
| url | https://doi.org/10.1038/s41467-023-36908-z |
| work_keys_str_mv | AT vincentpavot betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT catherineberry betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT michaelkishko betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT natalieganosova betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT luli betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT timtibbitts betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT deanhuang betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT aliceraillard betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT sylvianegautheron betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT cindygutzeit betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT margueritekoutsoukos betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT romanmchicz betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates AT valerielecouturier betavariantcovid19proteinboostervaccineelicitsdurablecrossneutralizationagainstsarscov2variantsinnonhumanprimates |